SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001104659-23-114279
Filing Date
2023-11-03
Accepted
2023-11-03 16:07:51
Documents
12
Period of Report
2023-11-01
Items
Item 3.01: Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 FORM 8-K tm2329650d1_8k.htm   iXBRL 8-K 30675
  Complete submission text file 0001104659-23-114279.txt   206104

Data Files

Seq Description Document Type Size
2 XBRL TAXONOMY EXTENSION SCHEMA bcli-20231101.xsd EX-101.SCH 3036
3 XBRL TAXONOMY EXTENSION LABEL LINKBASE bcli-20231101_lab.xml EX-101.LAB 34240
4 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE bcli-20231101_pre.xml EX-101.PRE 22373
6 EXTRACTED XBRL INSTANCE DOCUMENT tm2329650d1_8k_htm.xml XML 3323
Mailing Address 1325 AVENUE OF AMERICAS 28TH FLOOR NEW YORK NY 10019
Business Address 1325 AVENUE OF AMERICAS 28TH FLOOR NEW YORK NY 10019 201-488-0460
BRAINSTORM CELL THERAPEUTICS INC. (Filer) CIK: 0001137883 (see all company filings)

IRS No.: 207273918 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-36641 | Film No.: 231376376
SIC: 2836 Biological Products, (No Diagnostic Substances)